Overview


According to FutureWise analysis, the European Anti-Viral Therapies market in 2023 was US$15.69 billion, and is expected to reach US$29.74 billion by 2031 at a CAGR of 8.32%. This robust growth reflects the increasing demand for advanced antiviral treatments driven by emerging viral threats and an aging population more susceptible to viral infections. The market expansion is further supported by significant investments in research and development, with pharmaceutical companies focusing on next-generation antiviral drugs and personalized treatment approaches.
 
FutureWise Market Research has instantiated a report that provides an intricate analysis of Europe Anti-Viral Therapies Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Europe Anti-Viral Therapies Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AbbVie Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Johnson and Johnson Services, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the European Anti-Viral Therapies Market: 

AbbVie Inc.

  • On September 25, 2024, AbbVie voluntarily withdrew the marketing authorizations for Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) in the European Union, including Norway, Liechtenstein, and Iceland. The company cited commercial reasons for this decision. As a result, these antiviral therapies for chronic hepatitis C are no longer available in the EU.

GlaxoSmithKline plc

  • In October 2023, GSK obtained an exclusive worldwide license from Janssen (Johnson & Johnson) to further develop and commercialize JNJ-3989, a small interfering RNA (siRNA) targeting the hepatitis B virus. GSK plans to sequentially test this treatment in combination with its own antisense oligonucleotide, bepirovirsen, to improve the potential for achieving a functional cure in patients with chronic hepatitis B.
  • Portfolio expansion: At AASLD 2024, GSK spotlighted its hepatology programs, emphasizing bepirovirsen’s antiviral mechanisms (HBsAg suppression, immune stimulation) and the addition of daplusiran/tomligisiran (JNJ-3989) to its pipeline

AstraZeneca

  • At ESCMID Global 2025 in April, AstraZeneca presented data on its Vaccines and Immune Therapies portfolio, highlighting the effectiveness of the long-established Fluenz/FluMist flu vaccine and ongoing innovations against bacterial and viral respiratory infections.
  • In early 2025, AstraZeneca partnered with CEPI to develop a cost-effective VHH antibody candidate targeting multiple pandemic influenza strains (H1, H3, H5, H7). CEPI has pledged up to $43.5 million to support the program from preclinical proof-of-concept through Phase 1 trials.

F. Hoffmann-La Roche Ltd

  • Roche has published groundbreaking Phase III data from 2025 indicating that a single dose of Xofluza (baloxavir marboxil) reduces the transmission of influenza within households by 32%. This marks the first antiviral medication proven to decrease the spread of the virus. The findings have been submitted to both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

By Product Type

  • Generic Drugs
  • Branded Drugs

By Application

  • HIV
  • Hepatitis
  • Herpes
  • Influenza

By Mechanism of Action

  • Nucleotide Polymerase Inhibitor
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Region

  • Germany
  • U.K
  • France
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Europe Anti-Viral Therapies Market By Mechanism of Action, By Product Type, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— Germany, U.K, France, Italy, Spain, Russia, Poland, Rest of Europe.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customisation offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Europe Anti-Viral Therapies Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Product Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview

    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Europe Anti-Viral Therapies Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.   Europe Anti-Viral Therapies Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Product Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Product Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Europe Anti-Viral Therapies Market, By Product Type Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Generic Drugs
        2. Branded Drugs

  • 8.   Europe Anti-Viral Therapies Market, By Application Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza

  • 9.   Europe Anti-Viral Therapies Market, By Mechanism of Action Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Nucleotide Polymerase Inhibitor
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Others

  • 10.   Europe Anti-Viral Therapies Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 11.   Market Share Analysis and Competitive Landscape
    •   1. Europe Landscape - Key Players, Revenue and Presence
        2. Europe Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Europe Emerging Companies
        4. Europe - Market Share Analysis and Key Regional Players
        5. Europe Key Player - Growth Matrix
  • 12.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •       1. AbbVie Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. GlaxoSmithKline plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. F. Hoffmann-La Roche Ltd
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Johnson and Johnson Services, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview

  • 13.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 14.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

Related Market

Allogeneic T Cell Therapies Market

Read More

Plasma-Derived Protein Therapies Market

Read More

Oncolytic Virus Therapies Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11